Womens Malignancies Branch: News & Events

Clinical Trial Tests CAR T-Cell Therapy on Peritoneal Mesothelioma and Recurrent Ovarian Cancer 

The Mesothelioma Center at Asbestos.com, Dec 18, 2018

The National Cancer Institute (NCI) in Bethesda, Maryland, has opened an innovative clinical trial for patients with peritoneal mesothelioma that will explore the safety and effectiveness of a novel CAR T-cell therapy.  This clinical trial is also recruiting patients with recurrent ovarian cancer.  Learn more...

 Brain metastases developed from HER2 positive and triple negative breast cancer

ecancer conferences: San Antonio Breast Cancer Symposium (SABCS 2018)

Dr. Patricia Steeg speaks to ecancer at SABCS 2018 about how brain metastases can develop from metastatic HER2 positive and triple negative breast cancer.  Learn more...

 

CT scan from a trial participant

Phase II trial suggests new drug can shrink tumors in advanced ovarian cancer

CCR Clinical Trial News, Jan 25, 2018

In an ongoing phase II trial led by Jung-Min Lee, M.D., using the drug prexasertib led to decreases in tumor size in patients with advanced ovarian cancer, known as high-grade serous ovarian carcinoma, who currently have limited treatment options. Read more...

Christina M. Annunziata

Dr. Annunziata on efforts to prevent gynecologic cancers

OncLive, Aug 15, 2017

In this video, Christina M. Annunziata, M.D., Ph.D., discusses focusing efforts to prevent gynecologic cancers.  Learn more. . . 

Alexandra S. Zimmer, M.D.

The promise of olaparib for the treatment of HER2-negative breast cancer

Targeted Oncology, Jun 27, 2017

In this video, Alexandra, S. Zimmer, M.D., discusses the promising data seen thus far with olaparib (Lynparza) for the treatment of HER2-negative breast cancer.  Learn more...

Jung-Min Lee, M.D.

Jung-Min Lee, M.D., on ovarian cancer:  study results on checkpoint kinase inhibitors

The ASCO Post, 2016 ESMO Congress

In this video, Dr. Lee discusses findings of a phase II study of the cell cycle checkpoint kinase inhibitors LY2606368 and prexasertib monomesylate monohydrate in sporadic high-grade serous and germline BRCA mutation-associated ovarian cancer (Abstract 8550).  Learn more...


NCI Facebook Live Events